+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study



Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study



International Journal of Cardiology 168(3): 2494-2497



The aim of this randomized study was to investigate the effect of seven-day high-dose atorvastatin therapy on the incidence of peri-procedural myocardial infarction (PMI) in patients receiving long-term statin therapy. The patients with stable angina receiving statin therapy and referred for percutaneous coronary intervention (PCI) were randomized (ratio 1:1) to a 7-day pre-treatment with atorvastatin of 80 mg daily and subsequent PCI (Atorvastatin group), or immediate PCI (Control group). The incidence of PMI was based on serum concentration of creatine kinase myocardial band (CK-MB) mass and troponin I (TnI), which were measured prior to and between 16 and 24h post PCI. The values were considered as positive if they were elevated ≥ 3 times the upper limit normal. We randomized 202 patients (male 67%, 65.5 ± 9.2 years; 100 vs. 102 pts.). There were no significant differences in the baseline characteristics among the randomized groups. The incidence of PMI, based on post-interventional release of TnI and/or CK-MB mass was 15% in the Atorvastatin group vs. 14% in the Control group (p=0.80). One patient (3%) in Atorvastatin group suffered from MI between randomization and PCI. These results suggest that 7-day pre-PCI therapy with high-dose atorvastatin did not reduce the occurrence of PMI in patients receiving chronic statin therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 052827628

Download citation: RISBibTeXText

PMID: 23597577

DOI: 10.1016/j.ijcard.2013.03.002


Related references

Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. American Journal of Cardiology 104(5): 630-633, 2009

Effect of High-Dose Statin Pretreatment on the Incidence of Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: Grading the Evidence Through a Cumulative Meta-analysis. Clinical Cardiology 38(11): 668-678, 2016

High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention: a meta-analysis of twenty-four randomized controlled trials. Plos One 9(12): E113352, 2015

Effect of High-Dose Statin Pretreatment for Myocardial Perfusion in Patients Receiving Percutaneous Coronary Intervention (PCI): A Meta-Analysis of 15 Randomized Studies. Medical Science Monitor 24: 9166-9176, 2018

Myocardial Infarct Size in Patients on Long-Term Statin Therapy Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. American Journal of Cardiology 116(12): 1791-1797, 2016

Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. Journal of the American College of Cardiology 54(6): 558-565, 2009

Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing nonemergency percutaneous coronary intervention. American Journal of Cardiology 110(10): 1397-1404, 2013

Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a meta-analysis. Annals of Medicine 42(3): 171-177, 2010

Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. Journal of the American College of Cardiology 54(24): 2290-2295, 2010

Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury. American Journal of Cardiology 94(11): 1363-1366, 2004

Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction. Cardiology in Review 20(6): 319-324, 2013

Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Acc Current Journal Review 14(2): 45-0, 2005

Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. European Heart Journal 25(20): 1822-1828, 2004

Short-Term, High-Dose Atorvastatin Pretreatment to Prevent Contrast-Induced Nephropathy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention from the ARMYDA-CIN Atorvastatin for Reduction of MYocardial Damage during An. 2011

Comparison of the efficacy of periprocedural rosuvastatin versus atorvastatin treatment in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal 34(Suppl 1): 24-24, 2013